Displaying results 13 - 24 of 62
EASL Studio: Teatime - 25 June 2022 • Dr Virginia Hernández-Gea (Moderator), Assoc. Prof. Luca Valenti (Moderator), Prof. Aleksander Krag (Faculty), Prof. Ana Lleo (Faculty), Dr Eric Trépo (Faculty) ℹ️ Please click here to access the podcast version of this EASL Studio episode.
Rare Liver Diseases
EASL Studio: Midday Talks: Rare Liver Diseases - A growing landscape of opportunities and challenges - 25 June 2022 • Rare Liver Diseases: A growing landscape of opportunities and challenges Prof. Verena Keitel (Moderator), Prof. Emmanuel Tsochatzis (Moderator), Dr Christine Clemson (Faculty), Dr Scott Swenson (Faculty), Dr Pamela Vig (Faculty) This EASL Studio is supported by Albireo Pharma, Alexion Pharmaceuticals, and Mirum Pharmaceuticals Inc. ℹ️ Please click here to access the podcast version of this EASL Studio episode.
EASL Studio: London Calling - 25 June 2022 • Prof. Maria Buti (Moderator), Prof. Francesco Negro (Moderator), Prof. Laurie DeLeve (Faculty), Dr Manal El-Sayed (Faculty), Dr Philipp Schwabl This EASL Studio has been sponsored by Intercept Pharmaceuticals Europe Limited. The sponsor have had no editorial control over the content featured.
EASL Policy Dialogues Episode 1: Drug use, viral hepatitis, and Europe • Description In this first episode, the experts are discussing the multifaceted issue of drug use in relation to the hepatitis C elimination in Europe. How far are we from hepatitis C elimination in Europe? How are drug use and hepatitis C issues related? How can the work of the European Parliament contribute to eliminating hepatitis?
Education at EASL • Description EASL aims to be the prime resource for education and professional development in hepatology and liver related research. EASL strives to reach the following goals: Provide state-of-the-art education programmes for physicians, scientists, and other professionals Disseminate scientific and clinical practice knowledge Promote multidisciplinarity Watch this session at the International Liver CongressTM 2022, to hear the EASL Educational Committee present ongoing educational activities and discuss future challenges to improve current offerings. We would love to hear your feedback, please take the survey and help us to reach our goal of being the leader for education in hepatology!
EASL Studio S1 E1: Liver Cancer Awareness Month • Description Since 2020 EASL Studio has been a part of the International Liver Congress (ILC), bringing you the most up-to-date research live from the congress. But EASL Studio is evolving. EASL Studio is now a new platform through which we will be exploring hepatology every week, from every angle. Through live debates, interviews, and roundtable discussions, EASL Studio will be a chance to peak behind the scenes. Hear the expert’s opinion on the latest research. Discover what it’s like to be a young investigator. Meet the Nurses, the allied health professionals, and the patients they work with. Watch on-demand the first Session that was broadcasted on Wednesday 27 October 2021. Programme Time Title 00:00-04:12 Welcome and Introductions Thomas Berg, University Clinic Leipzig, Germany Maria Buti, Valle Hebron University, Spain 04:12-28:26 Topic 1: Raising awareness about Liver Cancer Nathalie Ganne-Carrié, Avicenne Hospital, France Peter Jepsen, University of Aarhus, Denmark 28:26-47:34 Topic 2: Liver Cancer Summit: Highlights from 2021 and what awaits us in 2022 Angela Lamarca, University of Manchester, United Kingdom Jean-Charles Nault, Avicenne Hospital, France 47:34-50:31 Closing remarks Thomas Berg, University Clinic Leipzig, Germany Maria Buti, Valle Hebron University, Spain
Ask EASL: podcast on Liver Cancer • Ask EASL is a new series of educational content dedicated to answering questions from patients and patient organisations on important topics around liver disease. In this audio interview conducted on the occasion of liver cancer awareness month, Dr. Massimo A. Iavarone, hepatologist at the Ospedale Maggiore in Milan, Italy, is answering key questions raised by the Liver Patients International (LPI) and PSC Support, two EASL-affiliated patient associations, both part of the EASL patient synergies project.
COVID-19 and the liver
Ask EASL: podcast on COVID-19 vaccination in patients with liver disease • Ask EASL is an ongoing series of educational podcasts dedicated to answering questions from patients and patient organisations on important topics around liver disease. In this episode, Professor Markus Cornberg is joined by Dr Christiane Eberhardt and Professor Daniel Shouval to answer a range of questions raised by EASL’s Patient Synergies regarding the recently approved COVID-19 vaccinations. They address topics including the reasons for the rapid development of the vaccines, whether immunocompromised liver transplant patients should receive the vaccine, real-world data from vaccination programmes worldwide and the potential duration of immunity.
Metabolism, Alcohol & Toxicity
Non-alcoholic fatty liver disease: A patient guideline • This patient guideline is intended for all patients at risk of or living with non-alcoholic fatty liver disease (NAFLD). NAFLD is the most frequent chronic liver disease worldwide and comes with a high disease burden. Yet, there is a lot of unawareness. Furthermore, many aspects of the disease are still to be unravelled, which has an important impact on the information that is given (or not) to patients. Its management requires a close interaction between patients and their many healthcare providers. It is important for patients to develop a full understanding of NAFLD in order to enable them to take an active role in their disease management. This guide summarises the current knowledge relevant to NAFLD and its management. It has been developed by patients, patient representatives, clinicians and scientists and is based on current scientific recommendations, intended to support patients in making informed decisions. Click here to download the short version and here to download the publication in PDF format. EASL NAFLD-NASH Patient Guideline Short Version Non-alcoholic fatty liver disease: A patient guideline